Fresenius SE Debt to Equity Ratio 2016-2023 | FSNUY
Current and historical debt to equity ratio values for Fresenius SE (FSNUY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Fresenius SE debt/equity for the three months ending September 30, 2023 was 0.00.
| Fresenius SE Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-09-30 |
$49.03B |
$32.96B |
1.49 |
| 2023-06-30 |
$49.05B |
$34.27B |
1.43 |
| 2023-03-31 |
$47.64B |
$34.54B |
1.38 |
| 2022-12-31 |
$46.57B |
$33.95B |
1.37 |
| 2022-09-30 |
$46.50B |
$34.40B |
1.35 |
| 2022-06-30 |
$46.91B |
$34.09B |
1.38 |
| 2022-03-31 |
$47.73B |
$34.32B |
1.39 |
| 2021-12-31 |
$50.49B |
$34.65B |
1.46 |
| 2021-09-30 |
$50.58B |
$33.24B |
1.52 |
| 2021-06-30 |
$51.23B |
$32.69B |
1.57 |
| 2021-03-31 |
$49.98B |
$33.17B |
1.51 |
| 2020-12-31 |
$46.40B |
$29.73B |
1.56 |
| 2020-09-30 |
$49.24B |
$30.63B |
1.61 |
| 2020-06-30 |
$46.58B |
$30.01B |
1.55 |
| 2020-03-31 |
$46.35B |
$29.74B |
1.56 |
| 2019-12-31 |
$45.28B |
$29.77B |
1.52 |
| 2019-09-30 |
$44.55B |
$29.69B |
1.50 |
| 2019-06-30 |
$44.45B |
$28.53B |
1.56 |
| 2019-03-31 |
$44.47B |
$29.34B |
1.52 |
| 2018-12-31 |
$48.77B |
$18.20B |
2.68 |
| 2018-09-30 |
$47.56B |
$17.23B |
2.76 |
| 2018-06-30 |
$48.42B |
$17.15B |
2.82 |
| 2018-03-31 |
$48.70B |
$17.07B |
2.85 |
| 2017-12-31 |
$35.51B |
$24.55B |
1.45 |
| 2017-09-30 |
$37.53B |
$24.88B |
1.51 |
| 2017-06-30 |
$35.06B |
$23.12B |
1.52 |
| 2017-03-31 |
$34.63B |
$23.36B |
1.48 |
| 2016-12-31 |
$28.80B |
$22.60B |
1.28 |
| 2016-09-30 |
$27.65B |
$21.12B |
1.31 |
| 2016-06-30 |
$28.65B |
$20.85B |
1.37 |
| 2016-03-31 |
$26.96B |
$19.87B |
1.36 |
| 2015-12-31 |
$27.95B |
$19.99B |
1.40 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$16.800B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
